Colorectal Cancer Clinical Trial
Official title:
Prospective, Open-labelled, Phase II Study, of the Administration of Desmopressin in Patients With Colorectal Cancer, With or Without Metastasis, With Rectal Bleeding, Before Treatment With Surgery and/or Chemotherapy and/or Radiotherapy.
Verified date | August 2017 |
Source | Laboratorio Elea S.A.C.I.F. y A. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this study is to find the maximum tolerated dose and preliminary efficacy of desmopressin as an haemostatic agent, when is administered to patients with colorectal cancer and rectal bleeding, before specific oncologic treatment with surgery and/or chemotherapy and/or radiotherapy.
Status | Completed |
Enrollment | 30 |
Est. completion date | August 2017 |
Est. primary completion date | July 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Patients > 18 to < 80 years of age who have signed the informed consent form - Histological diagnosis of rectal adenocarcinoma localized, locally advanced or metastatic - Treatment indication with chemotherapy and/or radiotherapy and/or surgery according to disease stage - Rectal bleeding associated with the primary tumor within 48 hours prior to study entry - Acceptable organ function to be able to participate in the study, performed within 14 days prior to admission; defined by the following parameters: - Electrocardiogram (ECG) without significant clinical abnormalities - Haemoglobin greater than or equal to 8 g/dL - Total leukocyte count greater than or equal to 4.0 x 10^9/L - Absolute neutrophil count greater than or equal to 1.5 x 10^9/L - Total platelet count greater to 100.0 x 10^9/L - Total bilirubin less than or equal to 1.5 times the upper limit of normality (ULN) - Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) less than or equal to 1.5 times upper limit of normality (ULN) - Creatinine clearance greater than 50 ml/min - Performance status (Eastern Cooperative Oncology Group [ECOG]) less than or equal to 2 - Patients with childbearing potential should use one of the following contraceptives methods: intrauterine devices, barrier methods and tubal ligation Exclusion Criteria: - Colorectal cancer without bleeding evidences - Pregnancy or lactation - Use of hormonal contraceptives or treatments with sexual hormones in general - Patients with other illnesses not adequately controlled such as congestive heart failure, arterial blood pressure, unstable angina, severe cardiac arrhythmia, thromboembolic disease, diabetes 1 or 2, any hidden coronary disease determined by previous assessments - Psychiatric diseases implying patient incompetence - Known hypersensitivity to desmopressin or vasopressin - Severe von Willebrand disease (vWD)(defined by vWF<10% Ui/dl) or 2B vWD (defined by increased platelet agregation induced by ristocetin at low concentration) or hemophilia A or B carriers - History of seizures - Renal insufficiency (Creatinine clearance < 50 ml/min), hyponatremia (serum sodium lower than the lower limit of normality-UNL)or previous history of hyponatremia - Syndrome of inappropriate antidiuretic hormone secretion (SIADH) - Positive serology for hepatitis B, C or known human immunodeficiency virus (HIV) infection - Known liver disease (cirrhosis, liver enzymes greater than or equal to 1.5 times the upper limit of normality or total bilirubin greater than or equal to 1.5 times the upper limit of normality - Active infections wich, according to the investigator judgement, coud interfere with patient safety - Other malignancies, with the exception of basal cell carcinoma, in situ cervical carcinoma, or any other tumour adequately treated and with a disease-free period greater than or equal to 5 years - Patients receiving or having received other investigational drugs 30 days prior to study entry |
Country | Name | City | State |
---|---|---|---|
Argentina | Hospital de Gastroenterologia ¨B.Udaondo¨ | Ciudad Autonoma de Buenos Aires | Buenos Aires |
Argentina | Instituto de Oncología "Alexander Fleming" | Ciudad Autónoma de Buenos Aires | Buenos Aires |
Lead Sponsor | Collaborator |
---|---|
Laboratorio Elea S.A.C.I.F. y A. |
Argentina,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Presence or absence of grade 3 or 4 adverse events related to the study drug, in a maximum of 2 out of 6 patients assessed in each dose level. | A total of 6 groups with 3 patients each, with different dose ranges and dosing schedules will be assessed. The number of patients in each group with grade 3 or 4 adverse events, including clinical or analytical findings, will be determined in order to stablish the maximum tolerated dose. |
Up to one week after the administration of the first dose | |
Secondary | Number of patients with grade 3 or 4 local adverse events | Once the maximum tolerated dose is determined, other 12 patients will be assessed to evaluate safety and tolerability of the study drug when administered as monotherapy. | Up to one week after the administration of the first dose | |
Secondary | Number of patients with grade 3 or 4 systemic adverse events | Once the maximum tolerated dose is determined, other 12 patients will be assessed to evaluate safety and tolerability of the study drug when administered as monotherapy. | Up to one week after the administration of the first dose | |
Secondary | Number of withdrawn from treatment | Up to one week after the administration of the first dose | ||
Secondary | Number of patients with partial or complete response in clinical endpoints | Clinical endpoints such us rectal bleeding, mucorrhea, evacuatory attempts and rectal pain will be assessed before and after treatment with the study drug. Response will be classified as complete or partial response. |
Up to one week after the administration of the first dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |